282
- VanArnumP. Biosimilars: market weaknesses and strengths. http://www.pharmtech.com/
biosimilars- market-weaknesses-and-strengths.. 2012. - Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13)
for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur
J Health Econ. 2014;15(Suppl 1):S65–71. - Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-
duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2
randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574–82. - von Schaper E. Celltrion’s infliximab copy shows path to biosimilars in US. Nat Biotechnol.
2016;34:454–5. - Cohen S, Genovese E, Choy E, et al. Randomized, double-blind, phase 3 study of efficacy and
safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid
arthritis. Arthritis Rheum. 2015;67:Abstract 2054. - Farkas K, Rutka M, Balint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction
therapy in Crohn’s disease and ulcerative colitis – experiences from a single center. Expert
Opin Biol Ther. 2015;15:1257–62. - Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in
patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol
Hepatol. 2015;30:1705–12. - Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimi-
lar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci.
2015;60:951–6. - Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clini-
cal and commercial considerations. Drugs. 2011;71:1527–36. - Food & Drug Administration. CT-P13 (infliximab biosimilar) briefing document for the
arthritis advisory committee meeting date: February 9, 2016. http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/
UCM484860.pdf. - National Conference of State Legislatures. State laws and legislation related to biologic medi-
cations and substitution of biosimilars. http://www.ncsl.org/research/health/state-laws-and-
legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx.
C.Y. Ha and A. Kornbluth